This 1 Bullish Move by Merck Could Drive Growth for Years to Come

On Jan. 8, pharmaceutical giant Merck (MRK 0.45%) moved to acquire biotech Harpoon Therapeutics, (HARP -0.76%) for $680 million in cash. The point of the acquisition, which should close in the first half of this year, is to gain access to Harpoon's technology and its pipeline of early-stage therapy candidates for various solid tumor cancers, including a pair that aim to treat small cell lung cancer and multiple myeloma.Overall, the move will bolster Merck's oncology pipeline directly, and it might also pave ...